Crescent Biopharma (CBIO) Net Cash Flow (2013 - 2026)

Crescent Biopharma (CBIO) has 14 years of Net Cash Flow data on file, last reported at -$24.0 million in Q1 2026.

• Net Cash Flow for Q1 2026 came in at -$24.0 million, down 94.47% year-over-year; the trailing twelve-month figure through Mar 2026 was $166.9 million (up 1133.3% YoY), and the FY2025 annual result was $178.6 million, up 674.63% from the prior year.
• Net Cash Flow slipped to -$24.0 million in Q1 2026 per CBIO's latest filing, from $80.0 million in the prior quarter.
• Over five years, Net Cash Flow peaked at $130.3 million in Q2 2025 and troughed at -$24.0 million in Q1 2026.
• A 5-year average of $7.3 million and a median of -$8.6 million in 2022 frame the typical range for Net Cash Flow.
• The sharpest annual moves came in 2022 and 2025: Net Cash Flow sank 201.0% in 2022, then jumped 1564.52% in 2025.
• A 5-year view of Net Cash Flow shows it stood at -$7.9 million in 2022, then grew by 3.75% to -$7.6 million in 2023, then surged by 556.56% to $34.8 million in 2024, then soared by 129.99% to $80.0 million in 2025, then tumbled by 130.01% to -$24.0 million in 2026.
• Business Quant data shows CBIO's Net Cash Flow at -$24.0 million in Q1 2026, $80.0 million in Q4 2025, and -$19.3 million in Q3 2025.